🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 670002401 (prev. 670002104 )
- Market Cap
- Mid Cap
- Previous Symbol
- NOX (changed 7/10/2001)
Business: Novavax, Inc. is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates. In addition, the company is developing its vaccine candidates for worldwide commercialization.
Notes: May 08, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Novavax expects that upon the opening of trading on May 10, 2019, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol “NVAX” and the new CUSIP number 670002401.
Company Contact
- CEO
- John C. Jacobs
- CFO
- Jim Kelly
- Headquarters
- 700 Quince Orchard Road, , Gaithersburg, MD 20878
- Phone
- 240-268-2000
- Fax
- 240-268-2100
- Investor Relations
- 240-268-2022 · ir@novavax.com